AU2007328210B2 - Intermediate duration neuromuscular blocking agents and antagonists thereof - Google Patents

Intermediate duration neuromuscular blocking agents and antagonists thereof Download PDF

Info

Publication number
AU2007328210B2
AU2007328210B2 AU2007328210A AU2007328210A AU2007328210B2 AU 2007328210 B2 AU2007328210 B2 AU 2007328210B2 AU 2007328210 A AU2007328210 A AU 2007328210A AU 2007328210 A AU2007328210 A AU 2007328210A AU 2007328210 B2 AU2007328210 B2 AU 2007328210B2
Authority
AU
Australia
Prior art keywords
neuromuscular
cysteine
och
glutathione
blocking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007328210A
Other languages
English (en)
Other versions
AU2007328210A2 (en
AU2007328210A1 (en
Inventor
John J. Savarese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of AU2007328210A1 publication Critical patent/AU2007328210A1/en
Publication of AU2007328210A2 publication Critical patent/AU2007328210A2/en
Application granted granted Critical
Publication of AU2007328210B2 publication Critical patent/AU2007328210B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2007328210A 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof Active AU2007328210B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87313206P 2006-12-06 2006-12-06
US60/873,132 2006-12-06
PCT/US2007/024914 WO2008070121A1 (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Publications (3)

Publication Number Publication Date
AU2007328210A1 AU2007328210A1 (en) 2008-06-12
AU2007328210A2 AU2007328210A2 (en) 2011-06-09
AU2007328210B2 true AU2007328210B2 (en) 2012-11-22

Family

ID=39492558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007328210A Active AU2007328210B2 (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Country Status (8)

Country Link
US (1) US8148398B2 (enExample)
EP (1) EP2101772B1 (enExample)
JP (1) JP5213137B2 (enExample)
CN (1) CN101588803B (enExample)
AT (1) ATE554769T1 (enExample)
AU (1) AU2007328210B2 (enExample)
CA (1) CA2671904C (enExample)
WO (1) WO2008070121A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101588803B (zh) 2006-12-06 2013-03-20 康乃尔研究基金会有限公司 中等持续时间神经肌肉阻断剂及其拮抗剂
AU2008222298A1 (en) * 2007-03-08 2008-09-12 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
WO2008117271A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
BRPI0809893A2 (pt) * 2007-05-01 2014-09-30 Chemagis Ltd Processo para prepar um sal de (1r-cis) - [(3,4 - dimetoxifenil) metil] - 1, 2,3,4 - tetraidro - 6,7 - dimetoxi - 2 - metil - 2 - carboxietil - isoquinolínio"
AU2008273724B2 (en) * 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
AU2008264802A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
US20100256381A1 (en) * 2007-07-09 2010-10-07 Chemagis Ltd. Process for producing cisatracurium and associated intermediates
AU2008320380A1 (en) * 2007-10-29 2009-05-07 Chemagis Ltd. Novel R,R'-atracurium salts
AU2009241211A1 (en) * 2008-05-01 2009-11-05 Chemagis Ltd. Cisatracurium derivatives, preparation and uses thereof
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
JP6236077B2 (ja) 2012-06-29 2017-11-22 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN110776481B (zh) 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN108727248B (zh) 2018-07-25 2021-05-25 四川大学华西医院 一类双季铵化合物及其制备方法和用途
TW202128628A (zh) * 2019-12-11 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 神經肌肉阻滯劑及其製備方法
WO2022082051A1 (en) * 2020-10-17 2022-04-21 Cornell University Methods for controlling and predicting recovery after nmba administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041960A2 (en) * 2003-10-28 2005-05-12 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
US4036959A (en) * 1974-10-29 1977-07-19 Millmaster Onyx Corporation Microbiocidal capped polymers
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
US4039682A (en) * 1976-03-29 1977-08-02 Baxter Travenol Laboratories, Inc. Method and composition for relief of back pain
JPS5455577A (en) * 1977-08-01 1979-05-02 Masachiyuusetsutsu Gen Hosupit Blocking agent of neuromuscle
US4192877A (en) * 1977-08-01 1980-03-11 Massachusetts General Hospital Neuromuscular blocking agents
US4235906A (en) * 1978-07-21 1980-11-25 Massachusetts General Hospital Bis-isoquinolinium compounds, compositions and methods of use
ATE921T1 (de) 1978-09-05 1982-05-15 Akzo N.V. Saeureadditionssalze von 2-beta, 16-beta-bis-piperidino-an drostan-16-beta-monoquaternaeren ammoniumderivaten und diese enthaltende pharmazeutische zusammensetzungen.
US4491665A (en) * 1979-10-19 1985-01-01 Burroughs Wellcome Co. Method of preparing isomers of bis isoquinolinium compounds
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
BG38182A1 (en) * 1983-06-21 1985-11-15 Ivanova Tocolytic means
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
DE3436179A1 (de) * 1984-10-03 1986-04-10 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung optisch aktiver amine
GB8518634D0 (en) * 1985-07-23 1985-08-29 Smithkline Beckman Corp Chemical compounds
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE4135710A1 (de) * 1991-10-30 1993-05-06 Basf Ag, 6700 Ludwigshafen, De Cyclische ammoniumverbindungen und ihre verwendung als glanzmittel fuer waessrig-saure galvanische nickelbaeder
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
US5739170A (en) * 1992-09-11 1998-04-14 The Regents Of The University Of California Inhibitors of metazoan parasite proteases
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
MA26476A1 (fr) 1997-03-25 2004-12-20 Cornell Res Foundation Inc Bloquants neuromusculaires a duree d' action ultra-courte
EP0971743B1 (de) * 1997-04-18 2006-07-12 Fritz Stanislaus Stabilisiertes arzneimittel enthaltend cysteinylderivate
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2001045697A1 (en) * 1999-12-21 2001-06-28 Kanebo, Limited Skin external agents and drugs
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US7763263B2 (en) * 2000-03-30 2010-07-27 Kao Corporation Skin external agents and drugs
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
AU2002219236B2 (en) * 2001-01-12 2006-02-09 Biogen International Gmbh Fumaric acid amides
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
KR101153250B1 (ko) * 2003-08-12 2012-06-05 니폰 조키 세야쿠 가부시키가이샤 글리시리진 고농도 제제
ES2763724T3 (es) * 2005-12-27 2020-05-29 Univ Ramot Preparaciones enzimáticas estables y métodos de uso de las mismas
CN101588803B (zh) 2006-12-06 2013-03-20 康乃尔研究基金会有限公司 中等持续时间神经肌肉阻断剂及其拮抗剂
US8592451B2 (en) * 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) * 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041960A2 (en) * 2003-10-28 2005-05-12 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Boros, E. E. et al., Journal of Medicinal Chemistry, 1999, vol. 42, pages 206-209 *
Boros, E. E. et al., Journal of Medicinal Chemistry, 2003, vol. 46, pages 2502-2515 *

Also Published As

Publication number Publication date
ATE554769T1 (de) 2012-05-15
AU2007328210A2 (en) 2011-06-09
AU2007328210A1 (en) 2008-06-12
CA2671904A1 (en) 2008-06-12
JP2010511715A (ja) 2010-04-15
EP2101772A4 (en) 2010-12-01
CN101588803A (zh) 2009-11-25
US8148398B2 (en) 2012-04-03
EP2101772A1 (en) 2009-09-23
US20080139482A1 (en) 2008-06-12
EP2101772B1 (en) 2012-04-25
JP5213137B2 (ja) 2013-06-19
CA2671904C (en) 2012-07-03
CN101588803B (zh) 2013-03-20
WO2008070121A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
AU2007328210B2 (en) Intermediate duration neuromuscular blocking agents and antagonists thereof
Ruetsch et al. From cocaine to ropivacaine: the history of local anesthetic drugs
JP2010511715A5 (enExample)
Lee Goodbye suxamethonium!
Mayer et al. Onset and recovery of rocuronium (Org 9426) and vecuronium under enflurane anaesthesia
EP2968225B1 (en) Neosaxitoxin combination formulations for prolonged local anesthesia
Yu et al. The development of local anesthetics and their applications beyond anesthesia
AU2019382168A1 (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
US20050192243A1 (en) Neuromuscular blocking agents and antagonists thereof
CA2165446C (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
Shukla et al. Comparative evaluation of haemodynamic effects and intubating conditions after the administration of org 9426 (rocuronium) and succinylcholine
EP3897594B1 (en) Dextroamphetamine and lisdexamfetamine to reverse dexmedetomidine sedation
WO2014210369A2 (en) Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108939052B (zh) 艾塞那肽在制备预防或治疗房颤的药物中的用途
US5756512A (en) Treatment of non-small cell lung carcinoma
CN112939896B (zh) 一种双季铵化合物及其制备方法和用途
Komori et al. Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias
JPH03505447A (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
Heinonen et al. Bradycardia during antagonism of pancuronium-induced neuromuscular block
CN110507652A (zh) 药物硝苯地平的新用途
ES2483940T3 (es) Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
Obdrzalek Althesin and thiopentone: a clinical comparison
US4217354A (en) Ketazocine anesthetic method of use
WO1992014469A1 (en) Treatment of ovarian cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 MAY 2011

FGA Letters patent sealed or granted (standard patent)